ETORICOXIB

Etoricoxib is a selective COX2 inhibitor reducing pain and inflammation while sparing gastric COX1. Side effects include edema, hypertension, and increased cardiovascular risk. Only GMP materials will be supplied, logistics all according to GDP.

SKU: 2a033e49ff7a Category: Tag:

Product Description


Mechanism of Action

Etoricoxib is a selective COX2 inhibitor that reduces prostaglandin synthesis involved in inflammation, pain transmission and fever. Its high COX2/COX1 selectivity aims to minimize GI toxicity associated with nonselective NSAIDs.

Benefits and Advantages

Used in COX2 selectivity assays, inflammationbiology research, prostaglandinpathway modelling, and selectiveNSAID comparative studies.

Side Effects and Risks

Risks include increased cardiovascular risk, hypertension, edema and rare GI complications. Handle with selectiveCOX2 inhibitor precautions.

Only GMP materials will be supplied, logistics all according to GDP.

Datasheet


Molecular Formula

C18H15ClN2O2S

Molecular Weight

358.8 g/mol

CAS Number

202409-33-4

Storage Condition

Store in a cool, dry place. Keep container tightly closed. Protect from moisture and light.

Solubility

3.28e-03 g/L

Purity

Purity information is available upon request (COA).

Synonym

Etoricoxib; 202409-33-4; Arcoxia; MK-0663; 5-Chloro-6'-methyl-3-(4-(methylsulfonyl)phenyl)-2,3'-bipyridine

IUPAC/Chemical Name

5-chloro-2-(6-methyl-3-pyridinyl)-3-(4-methylsulfonylphenyl)pyridine

InChl Key

MNJVRJDLRVPLFE-UHFFFAOYSA-N

InChl Code

InChI=1S/C18H15ClN2O2S/c1-12-3-4-14(10-20-12)18-17(9-15(19)11-21-18)13-5-7-16(8-6-13)24(2,22)23/h3-11H,1-2H3

References

https://pubchem.ncbi.nlm.nih.gov/compound/123619;

3D Conformer.

(Click, turn or enlarge)

Download our GMP API Product List.

MedicaPharma is an EU-based supplier of GMP-certified APIs that serves leading healthcare institutions and research organizations.
Click here to download our full API product list.

Download